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PRELIMINARY AND SHORT REPORTS
THERAPEUTIC ASSAYS OF THE SKIN AND CANCER UNIT OF THE NEW YORK
UNIVERSITY HOSPITAL*
ASSAY V.—TOCOPHEROLS (VITAMIN E) FOR Dscorn Luus ERYTHEMATOSUS AND OTHER
DERMATOSES
FRANCES PASCREE, M.D., H. H. SAWICKY, M.D., MABEL G. SILVEEBERG, M.D., MAX
BRAITMAN, M.D., AND NORMAN B. KANOF, M.D.
Although it has never been demonstrated conclusively that any condition in man is due
to a deficiency of vitamin E, this vitamin has been widely used, both experimentally and
clinically, in many branches of medicine (1). Its trial in cases of muscular dystrophy and of
primary fibrositis led to its use in conditions in which there are collagenous changes, and
reports have appeared in the dermatologic literature concerning its employment in lupus
erythematosus and other skin conditions (2—6).
Vitamin E is not a single substance but a complex mixture, and in evaluating results, the
composition of the particular preparation used should be known. It has been shown that the
aipha-tocopherol is most effective biologically, that the dextrorotatory isomer is more effec-
tive than the racemic form, and that the acetic acid ester is more potent than the alcohol
itself.
The therapeutic efficacy of tocopherols (vitamin E) was studied at the Skin and Cancer
Unit over a period of nine months from January to September 1949. Several staff members
participated in the study and their independent observations form the basis of this report.
The following dermatoses were treated:
Lupus erythematosus; chronic discoid 45
Scleroderma, generalized 1
Scleroderma, (acrosclerosis) 1
Necrobiosis lipoidica diabeticorum 1
Lichen sclerosus et atrophicus 1
Keloids, extensive 2
Poikiloderma vasculare atrophicans 1
Sarcoidosis (Boeck) 1
Radiodermatitic ulcer in Kaposi's sarcoma I
METHOD
Vitamin E capsulesf were prescribed to be taken before meals three times a day. The
patients were instructed to avoid the ingestion of mineral oil and other aperients. Concomi-
tantly vitamin E was administered parenterally twice weekly in one or both of two forms: a
synthetic preparation in some cases; the mixed tocopherols derived from natural sources
* From the Department of Dermatology and Syphilology of the New York University
Post-Graduate Medical School (Dr. Marion B. Sulzberger, Chairman) and the Skin and
Cancer Unit of the New York University Hospital.
t Tocopherex High Potency Capsules-Squibb, (containing 68 mg. of dl alpha-tocopheryl
acetate in oil, equivalent by rat anti-sterility test to 100 mg. of d alpha-tocopherol, the
amount present in 200 mg. tocopherex regular potency distilled, mixed, natural tocopherols.)
U.S. Vitamin Corporation kindly supplied the two forms of injectable vitamin E: (a)
ampules of 50 mgms. synthetic dl alpha tocopherol with sorbitan monolaurate as a solubil-
izer and 0.5% chlorbutinal and 2% procaine to control local pain; (b) anipules of 400 rngms.
distilled, mixed natural tocopherols equivalent to 100 mgms. of dl alpha tocopherol.
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in others; and each form injected alternately in a third group. The patients included in this
report received a minimum of six, an average of twenty, and a maximum of sixty injections.
The shortest period of treatment was two months, the average period was three and one-half
months, and the longest period of treatment was nine months. In one the case of idiopathic
hemorrhagic sarcoma (Kaposi), complicated by a radiodermatitic ulcer, vitamin E oint-
ment* was applied to the ulcer in conjunction with the oral and parenteral treatment.
SIDE EFFECTS
With few exceptions, both the oral and the intramuscular preparations of vitamin E were
tolerated well. Repeated blood counts and urinalyses failed to reveal any abnormality attrib-
utable to the therapy. Eight patients (2 of whom refused further treatment and are not
included in the final results) exhibited a severe local reaction at the site of injection, accom-
panied by a transient rise in temperature, chills, nausea and vomiting. Six of these reactions
occurred after the first injection of the synthetic preparation, one after the second, and one
after the third injection of the natural preparation. Many patients complained of pain,
ranging from mild to severe, at the site of injection. This was noted particularly following
the injection of the synthetic preparation.
One patient complained of severe flushing following each injection of the synthetic and
the natural preparation. Two patients experienced a recurrence of 'peptic ulcer' distress
while taking the oral preparation.
RESULTS
A. Results in lupus erythematosus
The cases of chronic discoid lupus erythematosus were classified into two groups, based
on the chronicity of the eruption:




2. Cases with a duration between 2 and 30 years:
Improved 2 (one relapsed)
Unimproved 21
Total cases 23
The overall incidence of improvement was low. Five out of forty-five (11%) cases showed
what may be designated as a fair response. In no case was the improvement striking
or the healing complete. The results, furthermore, were approximately the same in the
relatively early cases (duration less than two years) as in the more chronic cases (longer
than two years); 3 out of 22 responded in the first group, 2 out of 23 in the second group.
It may be of interest to compare the results with vitamin E therapy in chronic discoid
lupus erythematosus with the results obtained in comparable cases treated with Bistrimate
(R) [sodium bismuth triglycollamate (Smith)] (7) and with aurol-sulfide (R) [2% colloidal
gold sulfide (Rule)] and nicotinic acid (8). The results with vitamin Edo not approach those
obtained with the latter therapeitic agents. Morgan (9) likewise found vitamin E therapy
of little benefit in a group of 10 cases of lupus erythematosus.
B. Results in a miscellaneous group of cases
The results in this group of dermatoses were poor with three exceptions: some improve-
ment was noted in one of the two cases of extensive keloids; there was considerable improve-
* U. S. Vitamin Corporation kindly supplied the vitamin E ointment: 5% mixed natural
tocopherols in a carbowax base.
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ment in the case of sarcoidosis (Boeck) and in the case of radiodermatitic ulcer which healed
after three months of combined oral, iitramuscular and topical therapy. Little or no im-
provement was noted in one case of generalized seleroderma, one case of acroscierosis, one
case of necrobiosis lipoidica diabeticorum, one case of lichen scierosus et atrophicus and
one case of poikiloderxna vasculare atrophicans.
SUMMARY AND CONCLUSIONS
The effects of combined oral and parenteral tocopherol (vitamin E) therapy were studied
in 45 cases of chronic discoid lupus erythematosus, and in a group of miscellaneous erup-
tions.
The results in chronic discoid lupus erythematosus were unequivocally poor. A fair to
moderate degree of improvement after prolonged therapy was noted in only a small propor-
tion of cases. Forty out of 45 failed to respond.
The group of miscellaneous eruptions was too small to warrant any conclusive statement
as to the value of vitamin E in the treatment of these conditions.
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